Back to top
more

LivaNova (LIVN)

(Delayed Data from NSDQ)

$52.76 USD

52.76
537,422

+0.89 (1.72%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $52.80 +0.04 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?

LivaNova (LIVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 10.13% and 6.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 24.56% and 6.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Advances Cardiopulmonary Wing With Essenz ILBM

LivaNova's (LIVN) Essenz ILBM boasts B-Capta sensing technology, ensuring accuracy and compliance with Clinical Laboratory Improvement Amendments.

LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 34.48% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Beats Q1 Earnings and Revenue Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 4.88% and 8.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in LivaNova (LIVN): Can Its 12.7% Jump Turn into More Strength?

LivaNova (LIVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why You Should Hold Teladoc Health (TDOC) Stock Now

Teladoc Health (TDOC) remains well-poised for growth on the back of solid revenues, sustained demand for virtual care services and sufficient cash-generating abilities.

Neogen (NEOG) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

Neogen (NEOG) delivers core growth in both the Food Safety and Animal Safety segments amid macroeconomic headwinds in the third quarter.

Encompass Health (EHC) Opens JV Hospital for Oklahoma Patients

Encompass Health (EHC) inaugurated the Owasso-based Ascension St. John Rehabilitation Hospital, that it will operate jointly with Ascension St. John to offer rehabilitative care in Oklahoma.

LivaNova (LIVN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for LivaNova (LIVN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Dips

Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter.

SmileDirectClub (SDC) Q4 Earnings Beat, Gross Margin Down

SmileDirectClub (SDC) delivers an improved bottom line and cash flows in the fourth quarter despite a reduction in revenues.

Omnicell (OMCL) Q4 Earnings Beat Estimates, Margins Down

Omnicell (OMCL) delivers earnings and revenues in the fourth quarter exceeding the previously revised outlook amid macroeconomic challenges.

Alcon (ALC) Q4 Earnings Match Estimates, Margins Contract

Alcon (ALC) reports impressive CER growth in net sales across all segments in the fourth quarter amid a challenging macroeconomic environment.

Down -12.75% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)

LivaNova (LIVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

LivaNova (LIVN) Q4 Earnings and Revenues Beat Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 12.50% and 4.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Hologic, Inc. (HOLX) Hit a 52 Week High, Can the Run Continue?

Hologic (HOLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

HCA Healthcare (HCA) Rises 43% in 6 Months: More Room to Run?

HCA Healthcare (HCA) is well-poised for growth due to growing patient volumes, acquisitions and adequate cash-generating abilities.

LivaNova (LIVN) Beats Q3 Earnings and Revenue Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 1.75% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Expected to Beat Earnings Estimates: Should You Buy?

LivaNova (LIVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LivaNova (LIVN) Q2 Earnings and Revenues Surpass Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 3.92% and 2.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates

TransMedics (TMDX) delivered earnings and revenue surprises of -28.13% and 26.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Lags Q1 Earnings Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of -7.69% and 3.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Surpasses Q4 Earnings and Revenue Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 14% and 2.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?